2023年ESMO大会将于10月20日-24日在西班牙马德里举行，大会涵盖了肿瘤领域的基础研究、转化研究以及最新的临床研究进展，为临床实践、多学科讨论等提供广阔、卓越的学术平台。
近日，ESMO官方已公布除Late-breaking abstracts（LBA）外的所有口头摘要题目及作者信息。【肿瘤资讯】特别整理本次公布的肿瘤免疫疗法领域重磅研究（主要包含MO：mini oral；O：oral）标题，以飨读者。
Mini oral session
专场时间：2023年10月21日，16:30-18:00
专场地点：Málaga Auditorium - Hall 10
摘要号：1020MO
AdvanTIG-203：Ociperlimab（OCI）+替雷利珠单抗（TIS）治疗不可切除、局部晚期、复发/转移性食管鳞状细胞癌（ESCC）和程序性细胞死亡配体1（PD-L1）阳性患者的2期随机多中心研究
AdvanTIG-203: Phase 2 Randomized, Multicenter Study of Ociperlimab (OCI) + Tislelizumab (TIS) in Patients (pts) With Unresectable, Locally Advanced, Recurrent/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) and Programmed Cell Death-Ligand 1 (PDL1) Positivity
讲者：Feng Wang (中国广州)
摘要号：1021MO
etigilimab（抗TIGIT）和纳武利尤单抗（抗PD-1）治疗复发/晚期实体瘤的安全性和有效性
Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors
讲者：Meredith Mckean (Nashville, United States of America)
摘要号：1022MO
利用AI结合CT扫描的肿瘤总体积和肿瘤异质性预测接受免疫治疗的黑色素瘤和非小细胞肺癌患者的总生存率
Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy using AI combining total tumor volume and tumor heterogeneity on CT-Scans.
讲者：Lama Dawi (Paris, France)
摘要号：1023MO
解码免疫治疗耐药性：一种新的多参数磁共振成像方法分层癌症患者的结果
Decoding Immunotherapy Resistance: A Novel Multiparametric Magnetic Resonance Imaging Approach to Stratify Cancer Patient Outcomes
讲者：Kinga Bernatowicz (Barcelona, Spain)
摘要号：1024MO
在接受抗PD-1治疗的黑色素瘤患者中，AI识别的空间可解释性肿瘤微环境（TME）邻域与严重免疫相关不良事件（irAE）和进行性疾病（PD）相关
Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate with severe immune-related adverse events (irAE) and progressive disease (PD) in patients with melanoma treated with anti-PD-1-based therapy
讲者：Daniel Jimenez-Sanchez (Baltimore, United States of America)
摘要号：1025MO
RBS2418，一种口服ENPP1抑制剂，单独和联合帕博利珠单抗治疗实体瘤患者的初步安全性、药代动力学和免疫调节活性
Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors
讲者：Thomas U. Marron (New York, United States of America)
摘要号：1026MO
SHR-1701（一种双功能抗PD-L1/TGF-βRII药物）与贝伐珠单抗（BEV）联合治疗晚期实体瘤患者的1b/2期研究
A phase 1b/2 study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
讲者：徐瑞华 (中国广州)
Proffered Paper session
本专场有1个LBA摘要待确认（TBC）
专场时间：2023年10月23日，10:15-11:45
专场地点：Burgos Auditorium - Hall 3
专场主席：Alessandra Curioni-Fontecedro (Villar sur Glane, Switzerland) Gary Middleton (Birmingham, United Kingdom)
摘要号：1016O
对表面活性蛋白B的自身免疫驱动NSCLC患者的免疫检查点抑制剂相关肺炎
Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC
讲者：Lukas Flatz (Tuebingen, Germany)
摘要号：1017O
NTC-001：一项旨在测试BNT221（一种非工程化新抗原特异性T细胞产品）对晚期或转移性黑色素瘤患者的安全性和有效性的I期研究
NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma
讲者：Jessica S. Borgers (Amsterdam, Netherlands)
摘要号：1018O
GCC CAR-T治疗IM96治疗晚期癌症患者的I期研究
Phase I Study of GCC CAR-T therapy IM96 in Patients With Advanced Colorectal Cancer
讲者：Changsong Qi (Beijing, China)
摘要号：1019O
ADP-A2M4CD8 T细胞受体（TCR）T细胞单独或与纳武利尤单抗联合治疗实体瘤的1期SURPASS试验的临床和转化数据
Clinical and translational data from the Phase 1 SURPASS trial of ADP-A2M4CD8 T-cell receptor (TCR) T-cell therapy alone or combined with nivolumab in solid tumors
讲者：Victor Moreno Garcia (Madrid, Spain)
排版编辑：肿瘤资讯-云初
苏公网安备 32059002004080号
